Medical Device for Delivering a Polymer-Containing Drug Solution Based on Rheological Pretreatment and Drug Solution Delivery Method Using the Same

The drug delivery device addresses uneven delivery of high-viscosity solutions by applying mechanical shear in a fluid control region, enhancing uniformity and stability of polymer drug delivery through microneedles.

KR103042262B1Active Publication Date: 2026-11-06COLD PLA CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
KR1020260170631
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2026-09-08
Publication Date
2026-11-06
Estimated Expiration
2046-09-08

AI Technical Summary

Technical Problem

Conventional microneedle-based drug delivery devices struggle with delivering high-viscosity or high-flow resistance drug solutions, such as those containing polymers like hyaluronic acid, proteins, or nucleic acids, due to uneven supply and increased flow rate variation, which can degrade the solution's properties and lead to residual volume issues.

Method used

A drug delivery medical device that applies mechanical shear to the drug solution in a fluid control region before delivery through microneedles, using rheological pretreatment to temporarily reduce flow resistance and ensure uniform distribution.

Benefits of technology

The device effectively delivers high-viscosity drug solutions through microneedles while maintaining solution properties, reducing residual volume, and ensuring uniform dispersion and stability by controlling shear conditions and flow resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112026110875576-PAT00001_ABST
    Figure 112026110875576-PAT00001_ABST
Patent Text Reader

Abstract

The present invention relates to a medical device for delivering polymeric liquid drugs based on rheological pretreatment and a method for delivering liquid drugs using the same. The invention is characterized by performing a rheological pretreatment to temporarily reduce the flow resistance of the liquid drug by applying mechanical shear to the liquid drug before supplying the liquid drug containing a polymer to skin tissue through a plurality of microneedles, and by distributing and supplying the liquid drug with reduced flow resistance to the plurality of microneedles, thereby improving the delivery capability of the polymeric liquid drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a drug delivery medical device, and more specifically, to a medical device for delivering a drug solution to skin tissue that has relatively high viscosity or flow resistance by containing a polymer such as hyaluronic acid, protein, peptide, nucleic acid, polysaccharide, or derivative thereof, and a method for delivering the drug solution using the same.

[0002] In particular, the present invention relates to a drug delivery medical device and a drug delivery method using the same, for improving the delivery of a polymer drug solution by performing a rheological pretreatment to temporarily reduce the flow resistance of the drug solution by applying mechanical shear to the drug solution before supplying the drug solution containing a polymer to skin tissue through a plurality of microneedles, and distributing and supplying the drug solution with reduced flow resistance to the plurality of microneedles. Background Technology

[0003] Recently, drug delivery technologies utilizing multiple microneedles are being developed to directly deliver drugs or bioactive substances into skin tissue. Since drug delivery methods using microneedles can supply liquid medication through fine delivery pathways formed in the skin, they offer the advantages of reducing skin damage or pain compared to conventional injection methods and enabling the dispersed delivery of liquid medication to multiple locations.

[0004] Meanwhile, the drug solution delivered to the skin tissue may contain various physiologically active ingredients such as macromolecular substances like hyaluronic acid, or proteins, peptides, nucleic acids, and polysaccharides. Drug solutions containing such macromolecular substances may exhibit relatively high viscosity or flow resistance depending on the concentration, molecular weight, and intermolecular interactions of the macromolecular substances. In particular, when delivering the drug solution through microneedles with a small diameter and microchannels connecting them, it may be difficult to supply the drug solution smoothly due to high flow resistance.

[0005] When the flow resistance of a polymeric drug solution is high, methods such as applying a high supply pressure or increasing the discharge power of the drug supply unit may be considered to deliver the solution through microneedles. However, if the supply pressure is increased excessively, excessive pressure may be applied to the drug solution storage unit, connecting channel, distribution unit, or microneedles, and problems may arise such as increased flow rate variation among multiple microneedles or inability to smoothly deliver the drug solution to some microneedles.

[0006] In particular, when simultaneously delivering high-viscosity or high-flow resistance drug solutions using multiple microneedles, the supply volume of the drug solution may become uneven due to minute structural differences in the flow paths connected to each microneedle, differences in the load applied to the microneedles, or differences in the local condition of the skin tissue. Consequently, it may become difficult to achieve the target quantitative delivery or uniform dispersion of the drug solution.

[0007] Furthermore, when a drug solution is diluted or the concentration or composition of a polymer is altered to improve fluidity, the concentration of the active ingredient, physical properties, or biological characteristics of the solution may change. In particular, for drug solutions containing proteins, nucleic acids, or other physiologically active polymers, it is important to ensure that the physical or biological properties of the polymer are not degraded during the treatment process aimed at improving drug delivery.

[0009] Meanwhile, some polymeric solutions may exhibit rheological properties in which viscosity or flow resistance decreases with increasing shear rate or shear force, and after the shear is removed, the original flow characteristics may be recovered at least partially over time. Therefore, by utilizing the rheological properties of these polymeric solutions, there is a possibility of improving the delivery of the solution through microchannels and microneedles without altering the composition of the solution itself or applying excessive supply pressure.

[0010] However, conventional microneedle-based drug delivery devices primarily focus on methods of applying supply pressure to the drug solution to pump it toward the microneedles or supplying the drug solution after forming microchannels in the skin. Insufficient consideration has been given to a technology that actively applies mechanical shear to the drug solution in a separate fluid control area before it is supplied to the microneedles to temporarily reduce flow resistance, and supplies the drug solution to multiple microneedles while the reduced flow resistance is maintained.

[0011] Therefore, a new drug delivery technology is required that can temporarily reduce the flow resistance of a drug solution containing a polymer while substantially maintaining its properties, and stably and uniformly deliver the drug solution to skin tissue through multiple microneedles using the reduced flow resistance. Prior art literature

[0012] Patent Document 1: Republic of Korea Registered Patent Publication No. 10-1475301 The problem to be solved

[0013] The present invention was devised to solve the aforementioned problems and aims to provide a polymer drug delivery medical device using rheological pretreatment capable of smoothly delivering a drug solution containing a polymer and having relatively high flow resistance to skin tissue through a plurality of microneedles, and a drug delivery method using the same.

[0014] In addition, the invention aims to provide a drug delivery medical device and a drug delivery method capable of temporarily reducing the flow resistance of a drug solution by applying mechanical shear to the drug solution in a fluid control region before the drug solution is supplied to a plurality of microneedles, and supplying the drug solution with reduced flow resistance to the plurality of microneedles.

[0015] In addition, the purpose is to provide a drug delivery medical device and a drug delivery method capable of controlling mechanical shear applied to a drug solution in response to the type or rheological characteristics of the drug solution by controlling operating conditions such as the spacing between interfaces of the fluid control region, displacement of the interfaces, repetition rate, shear application time, and number of repetitions.

[0016] In addition, the purpose is to provide a drug delivery medical device and a drug delivery method that can effectively utilize the effect of rheological pretreatment in the drug delivery process by supplying the drug solution to a plurality of microneedles within a time interval during which the reduced flow resistance is maintained at least partially after the flow resistance of the drug solution is reduced by rheological pretreatment.

[0017] In addition, the purpose is to provide a drug delivery medical device and a drug delivery method capable of reducing the flow rate variation of the drug solution supplied to each microneedle by configuring the fluid resistance of multiple drug delivery pathways connected by multiple microneedles to be substantially uniform.

[0018] In addition, the purpose is to provide a drug delivery medical device and a drug delivery method capable of reducing the residual amount and loss of drug solution by moving the drug solution remaining in the fluid control area or distribution section to a plurality of microneedles during the drug solution delivery termination stage.

[0019] In addition, the purpose is to provide a drug delivery medical device and a drug delivery method that can more effectively deliver a drug solution into the skin tissue by applying electrical energy to the skin tissue, detecting the electrical characteristics of the skin tissue to determine the permeability state of the skin tissue, and linking the permeability state with the rheological pretreatment and supply timing of the drug solution. means of solving the problem

[0020] To solve the above-mentioned problems, a rheological pretreatment-based polymer drug delivery medical device according to one embodiment of the present invention is a drug delivery medical device for delivering a drug containing a polymer into skin tissue, comprising: a drug storage unit for receiving the drug; a fluid control unit provided downstream of the drug storage unit and including a fluid control region through which the drug passes and a flow characteristic control unit that applies mechanical shear to the drug located in the fluid control region to temporarily reduce the flow resistance of the drug; a flow path unit provided downstream of the fluid control region and moving the drug that has passed through the fluid control region to at least one drug delivery path; at least one microneedle provided to be insertable into skin tissue and delivering the drug supplied through the at least one drug delivery path to the skin tissue; and a drug supply unit that supplies the drug from the drug storage unit through the fluid control region and the flow path unit to the at least one microneedle. and a control unit that controls the operation of the flow characteristic control unit and the drug supply unit; wherein the control unit operates the flow characteristic control unit before the drug liquid is supplied to the at least one microneedle to apply mechanical shear to the drug liquid in the fluid control area, and controls the drug liquid, whose flow resistance is reduced by the mechanical shear, to be supplied to the at least one microneedle through the flow path unit.

[0021] In addition, the flow characteristic control unit is configured to impart mechanical shear to the chemical liquid located in the fluid control region by causing at least one boundary surface forming the fluid control region to be displaced relative to another boundary surface, and the at least one microneedle is characterized by being supported independently of the relative displacement of the boundary surface.

[0022] In addition, the control unit is characterized by being configured to control the mechanical shear applied to the liquid by controlling at least one of the displacement of the boundary surface, the repetition rate, the shear application time, and the number of repetitions in correspondence with the spacing between the boundary surfaces of the fluid control area.

[0023] In addition, the microneedles are provided in a plurality, and the flow path section includes a distribution section that distributes the liquid medicine supplied from the fluid control area into a plurality of branch flow paths each connected to the plurality of microneedles, wherein the plurality of branch flow paths are formed to have corresponding fluid resistances to reduce the flow rate variation of the liquid medicine supplied to the plurality of microneedles.

[0024] In addition, the flow characteristic control unit is characterized by reducing the viscosity of the chemical solution by applying mechanical shear to the chemical solution, and by applying the mechanical shear within a range where the reduced viscosity can be recovered over time after the mechanical shear is terminated.

[0025] In addition, the control unit is characterized by controlling the drug supply unit to supply the drug to the at least one microneedle by operating the drug supply unit within a time interval in which the reduced flow resistance is maintained at least partially after the flow resistance of the drug liquid is reduced by the application of mechanical shear by the flow characteristic control unit.

[0026] In addition, the control unit is characterized by initiating the operation of the drug supply unit within 60 seconds after the termination of the mechanical shear, thereby controlling the supply of the drug solution, in which at least some of the reduced flow resistance is maintained, to the at least one microneedle.

[0027] In addition, a deformable interface is provided along at least a portion of the fluid control region and the fluid channel, and the deformable interface is configured to sequentially deform from the fluid control region side toward the at least one microneedle side during the liquid drug delivery termination stage to reduce the internal volume, thereby moving the liquid drug remaining inside to the at least one microneedle side.

[0028] In addition, it further includes a flow state detection unit that detects state information indicating the supply of the above-mentioned drug solution or the operating state of the above-mentioned flow characteristic control unit, and the control unit is configured to adjust at least one of the operating conditions of the above-mentioned flow characteristic control unit or the supply conditions of the above-mentioned drug supply unit based on the state information detected by the flow state detection unit.

[0029] In addition, the polymer is characterized by comprising a polynucleotide (PN), a polydeoxyribonucleotide (PDRN), or a combination thereof.

[0030] In addition, the above flow characteristic control unit 500s to the above chemical solution -1 to 1500s -1 It is characterized by being configured to apply mechanical shear for 1 to 3 seconds at a shear rate.

[0031] Additionally, a discharge control unit is provided on the downstream side of the fluid control area to control the discharge of a chemical liquid moving from the fluid control area to the flow path side, and the control unit controls the discharge control unit to suppress the discharge of the chemical liquid from the fluid control area to the flow path side while mechanical shear is applied to the chemical liquid by the flow characteristic control unit, and controls the discharge control unit to supply the chemical liquid from the fluid control area to the flow path side after the mechanical shear is terminated.

[0032] In addition, a backflow prevention unit is provided on the upstream side of the fluid control area to suppress backflow of the chemical liquid from the fluid control area to the chemical liquid storage unit, and the backflow prevention unit is configured to suppress upstream movement of the chemical liquid while mechanical shear is applied to the chemical liquid by the flow characteristic control unit.

[0034] Meanwhile, in a replaceable drug delivery cartridge detachably coupled to a drug delivery medical device for delivering a drug solution containing a polymer to skin tissue according to one embodiment of the present invention, the cartridge comprises: an inlet portion into which the drug solution is introduced; a fluid control area through which the drug solution introduced through the inlet portion passes or is temporarily received; a shear generating structure that moves, vibrates, rotates, or deforms by a driving force transmitted from the outside to apply mechanical shear to the drug solution located in the fluid control area; a driving coupling portion connected to the shear generating structure and detachably coupled to a driving source provided in the drug delivery medical device to transmit the driving force of the driving source to the shear generating structure; and at least one drug delivery path provided downstream of the fluid control area through which the drug solution to which mechanical shear is applied moves. and at least one microneedle that is provided to be insertable into skin tissue and delivers a drug solution supplied through at least one drug delivery route to the skin tissue; wherein the shear generating structure comprises at least one of a movable boundary forming the fluid control region, a shear member provided inside the fluid control region, or a structure forming the fluid control region.

[0035] In addition, the shear generating structure is characterized by forming at least one boundary surface of the fluid control region and including a shear membrane that moves or deforms by a driving force transmitted from the outside.

[0036] In addition, the microneedles are provided in a plurality, and the replaceable drug delivery cartridge is provided between the fluid control area and the plurality of microneedles, and further includes a distribution unit that distributes the drug discharged from the fluid control area into a plurality of branching channels each connected to the plurality of microneedles.

[0037] Additionally, a discharge control unit is provided on the downstream side of the fluid control area to control the discharge of a drug liquid moving from the fluid control area to the at least one drug delivery path, and the discharge control unit is configured to suppress the discharge of the drug liquid from the fluid control area to the at least one drug delivery path while mechanical shear is applied to the drug liquid by the shear generation structure, and to discharge the drug liquid to the at least one drug delivery path after the mechanical shear is terminated.

[0038] In addition, the shear generating structure comprises at least a part or the whole of a structure forming the fluid control region, and the structure is driven by a driving force transmitted from the outside in a reciprocating motion, vibrating motion, rotational motion, eccentric rotational motion, oscillating motion, orbital motion, or a combination thereof, and is characterized in that a relative flow or velocity gradient is formed between the interface between the chemical liquid and the structure or between different locations within the chemical liquid by the driving of the structure.

[0039] In addition, the shear generating structure comprises a shear member provided within the fluid control area, and the shear member is configured to move, reciprocate, vibrate, or rotate by a driving force transmitted from the outside to form a relative flow or velocity gradient between the liquid and the shear member or within the liquid.

[0041] Meanwhile, a drug delivery method using a rheological pretreatment-based polymer drug delivery medical device according to one embodiment of the present invention is a drug delivery method using a drug delivery medical device configured to supply a drug containing a polymer through at least one microneedle, comprising: a step of supplying a drug contained in a drug storage unit to a fluid control area provided downstream of the drug storage unit; a flow characteristic control step of applying mechanical shear to the drug located in the fluid control area before the drug is supplied to the at least one microneedle to temporarily reduce the flow resistance of the drug; a step of supplying the drug that has undergone the flow characteristic control step to at least one drug delivery path through a flow path provided downstream of the fluid control area; and a step of supplying the drug supplied to the at least one drug delivery path to the at least one microneedle side.

[0042] In addition, the flow characteristic control step is characterized by applying mechanical shear to the liquid located in the fluid control region by displacing at least one boundary surface forming the fluid control region relative to another boundary surface, while the at least one microneedle is supported independently of the relative displacement of the boundary surface forming the fluid control region.

[0043] In addition, the above flow characteristic control step is characterized by controlling the mechanical shear applied to the chemical solution by controlling at least one of the displacement of the interface, the repetition rate, the shear application time, and the number of repetitions in correspondence with the spacing between the interfaces of the fluid control region.

[0044] In addition, the step of supplying the liquid medicine to the at least one microneedle is characterized by being performed within a time interval during which the flow resistance of the liquid medicine, reduced by the flow characteristic control step, is maintained at least partially.

[0045] Additionally, the method further comprises a residual drug discharge step in which, at the step of terminating the supply of the drug solution, a deformable interface forming at least a part of the fluid control area and the flow path is sequentially deformed from the fluid control area side toward the at least one microneedle side to reduce the internal volume, and the drug solution remaining in the fluid control area or the flow path is moved toward the at least one microneedle side.

[0046] In addition, the flow characteristic control step and the step of supplying the liquid medicine to the at least one microneedle are performed in overlap for at least a portion of the time interval, and during the overlapped time interval, at least a portion of the liquid medicine is supplied to the at least one microneedle through the flow path while mechanical shear is applied to the liquid medicine.

[0047] In addition, the flow characteristic control step comprises: a step of suppressing the outflow of a chemical liquid from the fluid control area to the flow path while mechanical shear is applied to the chemical liquid located in the fluid control area; and a step of supplying a chemical liquid from the fluid control area to the flow path after the mechanical shear is terminated. Effects of the invention

[0048] As described above, according to the present invention, by applying mechanical shear to the drug solution in a fluid control region before the drug solution containing a polymer is supplied to a plurality of microneedles to temporarily reduce the flow resistance of the drug solution, the effect is to more smoothly supply the polymer drug solution having relatively high viscosity or flow resistance to skin tissue through microchannels and microneedles.

[0049] In addition, by utilizing the rheological properties of the chemical solution to temporarily reduce flow resistance without diluting the solution itself or changing the concentration or composition of the polymer, it is possible to improve the delivery of the chemical solution while minimizing changes in its composition.

[0050] In addition, by applying mechanical shear to the liquid drug through the relative displacement of the interface forming the fluid control region and allowing the interface and a plurality of microneedles to be supported independently, the effect of the rheological pretreatment process on the liquid drug can be reduced on the skin insertion or support state of the microneedles.

[0051] In addition, since at least one of the displacement of the interface, the repetition rate, the shear application time, and the number of repetitions can be controlled in correspondence with the spacing between the interfaces of the fluid control region, there is an effect of being able to set appropriate shear conditions according to the type of chemical solution, the concentration of the polymer, or the rheological properties.

[0052] In addition, by supplying the drug solution to multiple microneedles within a time interval during which the flow resistance of the drug solution reduced by mechanical shear is maintained at least partially, the effect of improving the fluidity of the drug solution secured by rheological pretreatment can be effectively utilized in the actual delivery process of the drug solution.

[0053] In addition, by configuring the multiple branch channels connected from the distribution section to the multiple microneedles to have substantially the same fluid resistance, the variation in liquid flow rates between the multiple microneedles is reduced, and the liquid can be dispersed and delivered more uniformly.

[0054] In addition, by sequentially deforming the deformable interfaces forming the fluid control region and the distribution section at the end of the drug delivery stage to reduce the internal volume, the drug remaining inside the fluid control region or the distribution section is moved toward the microneedle, thereby having the effect of reducing the residual amount of drug and drug loss.

[0055] In addition, by applying electrical energy to the skin tissue and determining the electrical permeability state of the skin tissue based on the electrical characteristics of the skin tissue, and then supplying a drug solution with reduced flow resistance at a time corresponding to the target permeability state, the drug solution delivery efficiency can be improved by linking the state of the skin tissue with the flow state of the drug solution.

[0056] In addition, by using multiple electrode groups and multiple drug delivery groups corresponding to different areas of the skin tissue, it is possible to selectively supply the drug solution to the area of ​​the skin tissue that has reached the target permeability state and perform drug solution delivery corresponding to the local condition of the skin tissue.

[0057] In addition, by detecting the supply status of the drug solution or the operating status of the flow characteristic control unit and adjusting the operating conditions of the flow characteristic control unit or the supply conditions of the drug supply unit based on this, it is possible to perform more stable drug solution delivery in response to changes in the rheological properties or actual supply status of the drug solution. Brief explanation of the drawing

[0058] FIG. 1 is a schematic diagram illustrating the overall configuration of a polymer drug delivery medical device using rheological pretreatment according to one embodiment of the present invention. FIG. 2 is a conceptual diagram illustrating the internal structure of a fluid control unit according to one embodiment of the present invention and the operating principle of controlling flow characteristics by applying mechanical shear to a chemical liquid located in a fluid control area. FIG. 3 is a schematic diagram illustrating a drug delivery pathway and distribution structure between a distribution unit and a plurality of microneedles according to one embodiment of the present invention. FIG. 4 is a conceptual diagram illustrating the relationship between the time interval during which the reduced flow resistance is maintained at least partially and the time interval during which the liquid is supplied, after the flow resistance of the liquid is reduced by controlling the flow characteristics according to one embodiment of the present invention. FIG. 5 is an explanatory diagram illustrating a process in which, in the liquid delivery termination step according to one embodiment of the present invention, a deformable interface is sequentially deformed to move the liquid remaining in the fluid control area and the distribution section to a plurality of microneedles. FIG. 6 is an explanatory diagram illustrating the relationship for controlling the timing of drug delivery and flow characteristic control conditions based on the application of electrical energy to skin tissue and the detection of bio-information according to one embodiment of the present invention. FIG. 7 is an explanatory diagram illustrating a structure for selectively supplying a drug solution to a corresponding drug delivery group according to the correspondence between a plurality of electrode groups and a plurality of drug delivery groups and the target permeability state of the skin tissue according to an embodiment of the present invention. Specific details for implementing the invention

[0059] Hereinafter, exemplary embodiments according to the present invention will be described in detail with reference to the contents described in the attached drawings. In addition, a method of configuring and using an apparatus according to an embodiment of the present invention will be described in detail with reference to the contents described in the attached drawings. Identical reference numbers or symbols presented in each drawing indicate parts or components that perform substantially the same function. For convenience of reference, the directions of up, down, left, and right described below are based on the drawings, and the scope of the present invention is not necessarily limited to these directions.

[0061] The embodiments described in this specification are illustrative for more clearly explaining the technical concept of the present invention, and the scope of the present invention is not limited to the following embodiments. Furthermore, the shape, arrangement, coupling relationship, mode of operation, and control conditions of each component may be varied within the scope of the technical concept of the present invention.

[0062] The present invention relates to a medical device for delivering a drug solution containing a polymer into skin tissue and a method for delivering the drug solution.

[0063] Here, the chemical solution containing the polymer may include a chemical solution in which viscosity, flow resistance, or related rheological properties can be changed depending on the shear conditions. For example, the chemical solution may include polynucleotide (PN), PDRN (polydeoxyribonucleotide), hyaluronic acid, nucleic acid-based polymer, collagen, polysaccharide, hydrogel, or a mixture thereof, but is not limited thereto.

[0064] These polymer-containing liquids may possess relatively high viscosity or non-Newtonian flow characteristics, and flow resistance may increase when delivered through fine channels or multiple microneedles. In particular, when dispensing the liquid through multiple fine channels, high injection pressure may be required, variations in discharge volume may occur between channels, and there is a possibility of discharge delay or blockage in some channels. Furthermore, problems such as increased residual volume within the device or the requirement of excessive pressure may arise.

[0066] In order to alleviate this problem, the present invention applies mechanical shear to the liquid itself in a fluid control region provided upstream of the microneedle before the liquid reaches the microneedle.

[0067] In other words, the core of the present invention is not to repeatedly vibrate the microneedle itself, but to apply intentional mechanical shear to the drug solution in a fluid control area provided upstream of the microneedle to temporarily reduce the flow resistance of the drug solution, and to supply the drug solution with reduced flow resistance to the microneedle through a drug delivery pathway.

[0068] Here, the term “mechanical shear” as used in this specification does not mean only shear generated by a specific linear reciprocating motion or a specific actuator. The mechanical shear may include, for example, reciprocating shear, vibratory shear, rotational shear, shear due to membrane deformation, shear due to pulsating deformation, shear due to pressure fluctuation, shear due to acoustic or mechanical deformation, and combinations thereof.

[0069] In addition, the mechanical shear may include mechanical flow action that changes the flow characteristics of the chemical solution by forming a relative velocity difference or velocity gradient within the chemical solution. For example, the mechanical flow action may include elongation flow, flow formed by the contraction or expansion of a flow path, repetitive reciprocating flow or recirculation flow of the chemical solution, unsteady flow formed by pressure pulsation, and combinations thereof.

[0070] Therefore, mechanical shear in the present invention is not limited to a specific shear method or a specific flow pattern, and can be understood as a concept including rheological pretreatment that temporarily reduces the viscosity or flow resistance of the liquid by forming an intentional relative flow, velocity gradient, or mechanical deformation in the liquid located in or passing through the fluid control area (210).

[0071] Furthermore, the purpose of applying mechanical shear in this invention is not to intentionally cut or decompose the polymer, but to temporarily reduce the flow resistance of the chemical solution to improve delivery through the microchannels. Accordingly, the flow characteristic control conditions can be adjusted according to the type of chemical solution and the required delivery performance, and it is preferable to set them under conditions where excessive irreversible changes do not occur.

[0073] A polymer drug delivery medical device using rheological pretreatment according to the present invention is intended to deliver a drug containing a polymer into skin tissue and may include a drug storage unit (100), a fluid control unit (200), a flow path unit (300), a microneedle (400), a drug supply unit (500), and a control unit (600), as shown in FIG. 1.

[0074] The above-mentioned liquid storage unit (100) can accommodate a liquid containing a polymer to be delivered to skin tissue.

[0075] The above-mentioned liquid storage unit (100) may include an internal space for receiving liquid and may be configured in the form of a cartridge, ampoule, syringe, pouch, or a similar liquid receiving container. However, the specific shape and structure of the liquid storage unit (100) are not limited thereto.

[0076] The above-mentioned liquid storage unit (100) may be integrally provided with the medical device or may be detachably coupled to the medical device. If the liquid storage unit (100) is configured to be detachable, different liquid storage units (100) can be selectively installed and used depending on the type or amount of liquid used.

[0077] The above liquid storage unit (100) may be fluidly connected to the drug supply unit (500) described later, and the liquid contained in the liquid storage unit (100) may be supplied to the fluid control unit (200) depending on the operation of the drug supply unit (500).

[0078] Additionally, between the liquid storage unit (100) and the drug supply unit (500), a valve, a connecting passage, a sealing member, or a backflow prevention structure may be further provided as needed.

[0080] The above fluid control unit (200) is provided on the downstream side of the liquid storage unit (100) and can control the flow characteristics of the liquid before the liquid reaches the microneedle (400).

[0081] The above fluid control unit (200) may include a fluid control area (210) through which a chemical liquid passes or is temporarily received, and a flow characteristic control unit (220) that applies mechanical shear to the chemical liquid located in the fluid control area (210).

[0082] In the present invention, the fluid control region (210) may be provided upstream of the microneedle (400) so as to apply intentional mechanical shear to the liquid medicine before it reaches the microneedle (400). The fluid control region (210) is not necessarily limited to being provided in the form of an independent chamber, but may be formed in at least a part of a fluid space such as a flow path, pump room, valve region, distribution region, needle hub, or similar space where the liquid medicine passes through or is temporarily received between the liquid medicine storage unit (100) and the microneedle (400).

[0083] That is, in the present invention, mechanical shear is intentionally applied to the liquid medicine in the fluid control region (210) before the liquid medicine enters the microneedle (400), and accordingly, the liquid medicine can be supplied to the subsequent flow path (300) and microneedle (400) in a state where the flow resistance of the liquid medicine is reduced.

[0084] At this time, the mechanical shear is not limited to shear that occurs passively as the liquid medicine simply passes through the flow path, but can be generated by intentionally creating relative flow, velocity gradient, pressure fluctuation, or mechanical deformation in the liquid medicine through the driving or control of the flow characteristic control unit (220). Therefore, even if the specific shape or location of the fluid control area (210) is different, any area that can actively control the flow characteristics of the liquid medicine before it is supplied to the microneedle (400) can be used as the fluid control area (210) of the present invention.

[0085] In one embodiment, at least one of the interfaces forming the fluid control area (210) may be composed of a movable or deformable shear membrane. The shear membrane forms one surface of the fluid control area (210) and can be repeatedly moved or deformed by the operation of the flow characteristic control unit (220) to impart mechanical shear to the liquid located in the fluid control area (210).

[0086] A portion of the shear membrane may extend outward from the fluid control area (210) to form a drive coupling portion that is mechanically coupled to the drive source of the flow characteristic control portion (220). The drive coupling portion may be detachably coupled to the drive source, thereby allowing displacement generated from the drive source to be transmitted to the shear membrane.

[0087] The above driving source may include, but is not limited to, a voice coil actuator, a piezoelectric actuator, a linear resonant actuator, an electromagnetic actuator, or a combination thereof.

[0088] The above flow characteristic control unit (220) is not limited to a structure that moves or deforms the shear membrane described above. For example, at least a part of the upper plate, lower plate, side wall, or chamber housing forming the boundary surface of the fluid control area (210) may be directly moved, vibrated, rotated, or deformed to impart mechanical shear to the liquid. The boundary surface may be formed not only of a flexible membrane but also of a rigid plate or wall surface, and may be formed of at least one of a polymer material, glass, metal, ceramic, elastomer, or composite material.

[0089] Additionally, an internal shear member may be provided within the fluid control area (210) to move relative to the liquid or to change the flow of the liquid. The internal shear member may include at least one of a plate, a rib, a projection, a pin, a baffle, a mesh, a porous member, a curved portion, a constricted portion, or a flow direction changing portion, and may be configured to move or rotate by a driving source, or to increase the relative flow of the liquid or the local velocity gradient according to the movement of the fluid control area (210).

[0090] In another embodiment, part or all of the structure forming the fluid control area (210) may be driven by a driving source in a reciprocating motion, vibrating motion, rotational motion, eccentric rotational motion, oscillating motion, orbital motion, torsional motion, or a combination thereof. In this case, relative flow or velocity gradient may be formed between the liquid and the interface or between different locations within the liquid due to the acceleration, deceleration, or change of direction of the structure and the inertia, viscosity, interaction with the interface, and internal shape of the liquid, and thereby mechanical shear may be imparted to the liquid.

[0091] However, the interpretation is not limited to cases where mechanical shear is applied to the structure forming the fluid control area (210) and the liquid moving in the same manner without substantial relative flow, and the flow characteristics of the liquid can be controlled when relative flow, velocity gradient, inertial flow, circulating flow, vibrating flow, or similar flow changes are formed within the liquid by the driving of the structure.

[0093] As shown in FIG. 2, the fluid control area (210) can be formed between at least two boundary surfaces spaced apart from each other.

[0094] At least one of the above interfaces may be provided to be movable relative to another interface, and the flow characteristic control unit (220) may apply mechanical shear to the liquid located in the fluid control area (210) by causing displacement to at least one interface.

[0095] In FIG. 2, A conceptually represents the unilateral amplitude from the center position to the maximum displacement position in the repetitive relative motion of the boundary surface, and h represents the gap between the boundary surfaces forming the fluid control area (210).

[0096] The relative motion according to the above-mentioned unilateral amplitude (A) may occur in the plane direction of the boundary surface as exemplified in FIG. 2, but is not limited thereto.

[0097] For example, the relative motion may occur in at least one direction among the length direction, width direction, or thickness direction of the fluid control area (210), and may also occur in combination of displacements in multiple directions.

[0098] In addition, only one boundary surface may move while the other boundary surface is substantially fixed, or multiple opposing boundary surfaces may each move to form relative displacement.

[0099] Therefore, the relative displacement in the present invention is not limited to a structure in which a specific boundary surface is necessarily fixed or moves only in a specific direction.

[0100] The above flow characteristic control unit (220) can generate such relative displacement continuously or repeatedly.

[0101] For example, the flow characteristic control unit (220) can apply mechanical shear to the liquid located in the fluid control area (210) through reciprocating motion, vibrational motion, rotational motion, deformation of the membrane, pulsating deformation, pressure fluctuation, or a combination thereof.

[0102] The above flow characteristic control unit (220) may include a piezoelectric actuator, a voice coil actuator, an electromagnetic actuator, a linear actuator, an eccentric rotary type actuator, a magnetic actuator, a membrane drive type actuator, or a driving means capable of generating relative displacement between interfaces.

[0103] However, the technical feature of the present invention is not limited to using a specific actuator, but rather controls the flow characteristics of the liquid by applying controlled mechanical shear to the liquid located in the fluid control area (210).

[0105] Meanwhile, the shear condition applied to the liquid located in the fluid control area (210) may vary depending on at least one of the distance (h) between the interfaces, the unilateral amplitude (A), the repetition rate of the relative displacement, the shear application time, and the number of repetitions.

[0106] For example, if the interface moves back and forth periodically, the degree of shear applied to the liquid may increase as the gap (h) between the interfaces decreases, or as the unilateral amplitude (A) or repetition rate increases.

[0107] In the case of reciprocating motion as one example, the maximum shear rate formed in the fluid control area (210) can be determined by the one-sided amplitude (A) of the boundary surface, the repetition rate or frequency (f), and the gap (h) between the boundary surfaces, and can be roughly expressed by the following relationship 1.

[0109] [Relationship 1]

[0110] SR_max = 2πfA / h

[0112] Here, 'SR_max' represents the maximum shear rate roughly calculated based on the reciprocating motion, 'f' represents the speed or frequency at which the relative displacement of the boundary surface is repeated, 'A' represents the unilateral amplitude from the center position to the maximum displacement position in the repetitive relative motion of the boundary surface, and 'h' represents the gap between the boundary surfaces forming the fluid control area (210).

[0113] In addition, if the peak-to-peak displacement between the maximum displacement position and the minimum displacement position of the boundary surface is defined as D, based on symmetric reciprocating motion, the peak-to-peak displacement (D) corresponds to twice the unilateral amplitude (A), and the relationship D=2A can be formed. Accordingly, Equation 1 can be expressed as Equation 2 below.

[0115] [Relationship 2]

[0116] SR_max = πfD / h

[0118] Here, 'D' represents the peak-to-peak displacement between the maximum and minimum displacement positions of the boundary surface. Equation 2 above expresses the shear conditions substantially identical to Equation 1 based on peak-to-peak displacement.

[0119] The above equations 1 and 2 are exemplary for explaining the relationship between the shear condition formed in the fluid control area (210), the one-sided amplitude (A) or peak-to-peak displacement (D), the repetition rate or frequency (f), and the gap (h) between the interfaces. The shear rate formed in the actual chemical solution may vary depending on the shape of the fluid control area (210), the composition and rheological properties of the chemical solution, the temperature, the shape of the interfaces, and the method of movement.

[0121] Accordingly, the control unit (600) may not control the flow characteristic control unit (220) by limiting it to a specific frequency or one-sided amplitude, but may set the shear condition applied to the liquid by considering at least one of the gap (h) between the interfaces, one-sided amplitude (A), the repetition rate of relative displacement, the application time of mechanical shear, and the number of repetitions.

[0122] The above control unit (600) may use at least one of the relative displacement amount of the interface, unilateral amplitude, peak-to-peak displacement, repetition rate or frequency, number of reciprocating cycles, distance between interfaces, shear application time, and cumulative deformation amount, in addition to the shear rate, to set the mechanical shear conditions applied to the liquid.

[0123] Additionally, as an indicator for determining the state of flow characteristic control of the drug solution, at least one of the following may be used: a change in viscosity before and after flow characteristic control, a change in flow resistance, a supply pressure required to form a set flow rate, a driving load of the drug supply unit (500), or a value calculated or estimated from these.

[0124] Accordingly, the control unit (600) is not limited to controlling the flow characteristic control unit (220) based only on a preset shear rate, but can adjust at least one of the above parameters in response to the actual flow state of the liquid or the operating state of the device.

[0125] In particular, the control unit (600) can adjust at least one of the unilateral amplitude (A), repetition rate, shear application time, and number of repetitions in correspondence with the gap (h) between the boundary surfaces.

[0126] Accordingly, even if the shape of the fluid control area (210) or the gap between the boundary surfaces changes, the operating conditions of the flow characteristic control unit (220) can be adjusted so that the mechanical shear conditions required for the chemical solution are formed.

[0127] In this way, the shear conditions applied to the liquid can be set by adjusting the spacing between the interfaces of the fluid control area (210), the unilateral amplitude, the repetition rate, and the shear application time.

[0128] In one embodiment, the shear rate imparted to the drug solution is about 100s -1 to 3,000s -1 It can be set within the range of, more specifically about 500s -1 to 1,500s -1 It can be set within the range. In addition, the application time of mechanical shear can be set within the range of about 0.1 seconds to 10 seconds, and more specifically, within the range of about 1 second to 3 seconds.

[0129] For example, about 1,000s in a drug solution containing polynucleotide (PN) -1Mechanical shearing can be applied for about 2 seconds at a shearing rate. However, the above numerical range may vary depending on the composition, concentration, temperature, shape of the fluid control area (210), and required liquid delivery conditions of the liquid, and the present invention is not limited to specific numerical conditions.

[0130] The viscosity or flow resistance of the liquid may be temporarily reduced by the application of such mechanical shear.

[0131] In particular, the mechanical shear conditions applied to the drug solution can be set by considering not only the required degree of flow resistance reduction but also the operating time, operating load, power consumption, and potential temperature rise of the drug solution of the medical device. In the experiment of the present invention, approximately 1,000 s -1 Since it was confirmed that the viscosity of the liquid decreases significantly even at the shear rate, shear conditions can be set so as not to apply an unnecessarily high shear rate in the design of actual medical devices, within the range where the required degree of flow resistance reduction is secured.

[0132] For example, 2,000s -1 or 3,000s -1 Higher shear rate conditions, such as those mentioned above, may be applicable depending on the type, concentration, and structure of the liquid solution. However, if the required changes in flow characteristics at lower shear rates are already achieved, such high shear conditions may not be applied, taking into account the procedure time, driving load, power consumption, potential temperature rise of the liquid solution, and potential irreversible changes to the polymer. Therefore, in actual medical devices for procedures, shear conditions can be selected that ensure overall operating time and device efficiency while sufficiently controlling the flow characteristics of the liquid solution.

[0133] As such, the application time of mechanical shear can affect the behavior of the recovery of the flow characteristics of the chemical solution after the shear is completed. For example, under the same or similar shear rate conditions, as the shear application time increases, there may be a tendency for the reduced viscosity or flow resistance state to be maintained for a longer period or for its recovery to be delayed. However, the specific relationship between the shear application time and the recovery rate may vary depending on the type, concentration, temperature, and shear conditions of the chemical solution, and the two are not necessarily limited to having a linear or proportional relationship.

[0135] When mechanical shear is applied to the liquid by the above flow characteristic control unit (220), the viscosity or flow resistance of the liquid may be temporarily reduced.

[0136] Here, the reduction in flow resistance of the liquid does not mean only a specific rheological phenomenon, but may include various changes in rheological properties in which the pressure or flow resistance required for the liquid to move along the flow path decreases depending on the application of mechanical shear.

[0137] Therefore, the present invention is not limited to cases where the chemical solution necessarily exhibits typical shear thinning behavior.

[0138] Additionally, the flow characteristic control unit (220) is not intended to intentionally cut or decompose the polymer contained in the drug solution, but rather to temporarily change the flow characteristics of the drug solution so that the drug solution can pass more smoothly through the flow path (300), drug delivery path (310), and microneedle (400).

[0139] Accordingly, the flow characteristic control unit (220) can operate to apply mechanical shear within a range where excessive irreversible changes do not occur in the liquid.

[0140] In particular, the liquid may have the characteristic that its viscosity decreases upon application of mechanical shear, and after the mechanical shear is terminated, the reduced viscosity recovers at least partially over time.

[0142] As shown in FIG. 4, the flow resistance of the liquid can decrease after the point (t1) when mechanical shear is applied, and can gradually recover over time after the mechanical shear ends.

[0143] In FIG. 4, 'R0' represents the reference flow resistance of the chemical solution before mechanical shear is applied, 't0' represents the initial point before flow characteristic control, and 't1' represents the point at which flow characteristic control begins. Additionally, 't2' conceptually represents the point at which the flow resistance of the chemical solution decreases and reaches a reduced state, and 't3' represents the point at which the chemical solution supply time interval (Td) ends.

[0144] The curve shown in Fig. 4 conceptually illustrates the reduction and recovery behavior of such flow resistance, and the actual degree of reduction in flow resistance, recovery speed, and shape of the curve may vary depending on the composition of the liquid, temperature, shear conditions, and fluid structure of the medical device.

[0145] In addition, the reduced flow resistance does not immediately return to the state before the shear was applied immediately after the mechanical shear ends, and the reduced state can be maintained for at least a certain period of time.

[0146] Accordingly, the control unit (600) can operate the drug supply unit (500) to supply the drug to the flow path unit (300) and the microneedle (400) within a time interval during which the reduced flow resistance is maintained after the flow resistance of the drug liquid is reduced by the application of mechanical shear.

[0147] In Fig. 4, 'Td' conceptually represents the time interval for supplying the above-mentioned drug solution.

[0148] The above liquid supply time interval (Td) can be set in all or part of the time interval during which the state in which the flow resistance of the liquid is reduced is maintained at least partially.

[0149] Accordingly, since the drug solution can be supplied through multiple drug delivery pathways (310) while having relatively low flow resistance, the pressure required for supplying the drug solution can be relieved and the stability of drug solution delivery through multiple microneedles (400) can be improved.

[0151] Meanwhile, in one embodiment, an outflow control unit may be provided on the downstream side of the fluid control area (210) to control the outflow of the liquid moving from the fluid control area (210) to the flow path (300).

[0152] The above-mentioned outflow control unit may be configured to suppress the outflow of the liquid to the flow path (300) while mechanical shearing is applied to the liquid located in the fluid control area (210), and to supply the liquid to the flow path (300) after the application of the set mechanical shearing is completed.

[0153] For example, the above-mentioned outflow control unit may include a valve, an opening / closing member, a variable flow path, a flow limiting unit, or a flow path control means capable of controlling the movement of the liquid medicine in a similar manner, provided on the discharge side of the fluid control area (210).

[0154] The control unit (600) controls the outflow control unit while mechanical shearing is applied to the liquid by the flow characteristic control unit (220) to suppress the outflow of the liquid from the fluid control area (210) to the flow path (300), and after the mechanical shearing ends, controls the outflow control unit to supply the liquid with reduced flow resistance to the flow path (300).

[0155] At this time, suppressing the outflow of the chemical solution is not necessarily limited to completely closing the discharge side of the fluid control area (210), and may include limiting or controlling the downstream movement of the chemical solution so that the mechanical shear required for the chemical solution can be applied. In addition, the application of mechanical shear and the downstream supply of the chemical solution do not necessarily need to be performed in completely separate time intervals, and may be controlled so that some time intervals overlap before and after the end of the mechanical shear.

[0156] Additionally, a backflow prevention unit may be provided on the upstream side of the fluid control area (210) to prevent the chemical liquid from flowing back toward the chemical liquid storage unit (100) during the process of applying mechanical shear. The backflow prevention unit may include a check valve, a slit valve, an elastic sealing member, a valve structure that allows unidirectional flow, or a similar structure capable of preventing upstream backflow of the chemical liquid. Accordingly, the upstream movement of the chemical liquid is restricted while mechanical shear is applied to the chemical liquid in the fluid control area (210), and the required shear conditions within the fluid control area (210) can be formed more stably.

[0158] The above-mentioned Euro section (300) is provided on the downstream side of the fluid control section (200) and can move the liquid medicine that has passed through the fluid control section (200) to the microneedle (400).

[0159] The above-mentioned Euro section (300) may include a drug delivery path (310) through which a drug solution travels, and a drug solution with controlled flow characteristics in a fluid control area (210) may travel toward the microneedle (400) through the drug delivery path (310).

[0160] When a plurality of microneedles (400) are provided, the flow path (300) may include a distribution section for distributing the liquid medicine supplied from the fluid control area (210) to the plurality of microneedles (400). The distribution section may include a plurality of branch flow paths (320) corresponding to each of the plurality of microneedles (400).

[0161] The above-mentioned Euro section (300) may include at least one inlet side flow path into which a chemical solution supplied from a fluid control area (210) flows, and a plurality of branch flow paths (320) branching in multiple directions from the inlet side flow path.

[0162] As illustrated in FIG. 3, a plurality of branch channels (320) can each be connected to a corresponding drug delivery channel (310), and a drug solution can be supplied to each microneedle (400) through the drug delivery channel (310).

[0163] Here, the drug delivery path (310) may refer to a path through which the liquid drug travels from the downstream side of the fluid control unit (200) to each microneedle (400), and the branch path (320) may refer to a path that distributes the liquid drug in multiple directions among the components forming the drug delivery path (310).

[0164] Therefore, the drug delivery path (310) is not limited to a specific shape or a single flow path section, and can be understood as a concept including a branched flow path (320) formed inside the flow path section (300) and a connecting flow path extending toward the microneedle (400).

[0165] The plurality of branch channels (320) can be formed so as to reduce the flow rate variation of the liquid supplied to each microneedle (400).

[0166] To this end, a plurality of branch channels (320) may be formed to have corresponding fluid resistances. For example, by adjusting at least one of the length, cross-sectional area, diameter, width, height, curvature, and number of branches of each branch channel (320), the fluid resistance of each drug delivery path (310) may be formed to be within the same or similar range.

[0167] When multiple microneedles (400) are provided, the amount of liquid delivered in one go can be set based on the total amount of liquid delivered through the multiple microneedles (400), and the individual amount delivered through each microneedle (400) can be determined according to the fluid resistance of the branching path (320), the distribution structure, and the number of microneedles (400).

[0168] In this way, the shape or flow path structure of the branching path (320) for adjusting the difference in fluid resistance between the plurality of drug delivery paths (310) can function as a fluid resistance correction part. The fluid resistance correction part can be configured to reduce the deviation in the amount of drug liquid supplied or the flow rate between the plurality of microneedles (400) by forming at least one of the length, cross-sectional area, diameter, width, height, curvature shape, branching structure, orifice, or flow limiting structure of each drug delivery path (310) differently or correspondingly.

[0169] However, the plurality of branch channels (320) are not necessarily formed to have completely identical fluid resistance, and the fluid resistance of each branch channel (320) may be set differently depending on the amount of liquid supplied or discharge conditions required between the plurality of microneedles (400).

[0170] For example, if the drug delivery path (310) to a microneedle (400) at a specific location is longer than the drug delivery path (310) to a microneedle (400) at another location, the difference in fluid resistance of the entire drug delivery path (310) can be reduced by adjusting the cross-sectional area or shape of the branching path (320).

[0172] Additionally, the Euro section (300) may be further provided with a pressure balancing section, a flow limiting section, an orifice, or similarly for controlling the flow rate deviation between multiple drug delivery paths (310) as needed.

[0173] The flow path (300) illustrated in FIG. 3 illustrates a symmetrical distribution structure in which the liquid is branched in stages as one example, but the present invention is not limited thereto. The flow path (300) may be composed of a radial distribution structure, a tree-type distribution structure, a multi-stage branching structure, or a combination thereof.

[0174] In this way, the Euro section (300) is configured to reduce the difference in fluid resistance between multiple drug delivery paths (310), thereby allowing the drug liquid with reduced flow resistance to pass through the fluid control section (200) to be distributed more stably to multiple microneedles (400).

[0176] The above microneedle (400) is configured to be insertable into skin tissue and can deliver a drug solution supplied from the flow path (300) into the skin tissue.

[0177] The above microneedles (400) may be provided in multiple numbers, and each microneedle (400) may be fluidly connected to a corresponding drug delivery route (310).

[0178] The number, spacing, length, diameter, and arrangement shape of the above microneedles (400) can be varied depending on the type of liquid to be delivered, the characteristics of the skin tissue, the target delivery depth, and the amount delivered in a single session.

[0179] In one embodiment, the microneedle (400) may include nine microneedles arranged in a 3×3 array. In this case, the liquid with controlled flow characteristics in the fluid control area (210) may be supplied to the nine microneedles (400) through the flow path (300).

[0180] When a plurality of microneedles (400) are provided, the flow path (300) may include a plurality of drug delivery paths (310) corresponding to each microneedle (400), and may include a distribution section for distributing the drug liquid to the plurality of drug delivery paths (310) as needed.

[0181] However, the above 3×3 array and 9 microneedles are merely one example, and the number and arrangement of the microneedles (400) are not limited thereto.

[0182] In one embodiment, the microneedle (400) may be composed of a hollow microneedle having a hollow channel through which a drug solution travels. In this case, the drug solution supplied through the drug delivery route (310) may be delivered to the skin tissue through the internal hollow channel of the microneedle (400) and through an outlet formed at the tip or side of the microneedle (400).

[0183] In another embodiment, the microneedle (400) may be configured such that a groove or a channel is formed along its outer surface through which the liquid medicine can move. In this case as well, the liquid medicine can be supplied from the channel portion (300) to each microneedle (400) and delivered into the skin tissue along the outer surface of the microneedle (400).

[0184] Therefore, the microneedle (400) in the present invention is not limited to a specific drug delivery structure, and various microneedle structures capable of delivering a drug with controlled flow characteristics in the fluid control unit (200) into the skin tissue may be applied.

[0186] Meanwhile, multiple microneedles (400) can be divided into two or more drug delivery groups (410).

[0187] Each drug delivery group (410) may include one or more microneedles (400), and a drug solution may be selectively supplied to at least one of the plurality of drug delivery groups (410) under the control of the control unit (600).

[0188] The specific grouping method of the above drug delivery group (410) can be set according to the location of the microneedle (400), the treatment area of ​​the skin tissue, the order of drug delivery, or the correspondence with the electrode group (720) described later.

[0189] The arrangement of drug delivery groups (410) shown in FIG. 7 represents one example of such grouping, and the number of groups and the number of microneedles (400) included in each group are not limited thereto.

[0191] Meanwhile, in one embodiment, at least a portion of the fluid path in contact with the liquid medicine and the microneedle (400) may be provided in a replaceable cartridge or tip that is detachably coupled to the main body of the medical device.

[0192] The cartridge or tip may include an inlet for introducing a liquid medicine, a fluid control area (210), a movable or deformable shear membrane forming at least one boundary surface of the fluid control area (210), a driving coupling connected to the shear membrane, a flow path (300), a drug delivery path (310), and a microneedle (400).

[0193] However, the shear-generating structure of the above-mentioned replaceable cartridge or tip is not limited to the shear membrane. In other embodiments, the shear-generating structure may include at least a part or the whole of a movable boundary forming a fluid control area (210), a shear member provided inside the fluid control area (210), or a structure forming the fluid control area (210). The shear-generating structure may be detachably coupled to a driving source and a driving coupling part provided in the main body of the medical device, and may be moved, reciprocated, vibrated, rotated, or deformed by a driving force transmitted from the outside to form a relative flow or velocity gradient between the liquid and the boundary surface or the shear member, or between different locations inside the liquid.

[0194] The shear membrane can be moved or deformed by a driving force transmitted from the outside to apply mechanical shear to the liquid located in the fluid control area (210). The driving coupling connected to the shear membrane may be exposed to the outside of the cartridge or tip and may be detachably coupled to the driving source of the flow characteristic control unit (220) provided in the main body of the medical device.

[0195] In one embodiment, the fluid control area (210) may be formed between a shear membrane positioned on the upper side and a boundary surface positioned on the lower side opposite the shear membrane. The fluid control area (210) may be formed as an area having an area of ​​approximately 12 mm × 12 mm, and the gap between the opposing boundary surfaces may be set to approximately 0.38 mm to 0.5 mm. Additionally, depending on the shape of the fluid control area (210), the structure of the inlet and outlet sections, the shape of the boundary surface, etc., the effective internal volume of the fluid control area (210) may be set to a range of approximately 50 μL to 60 μL.

[0196] Meanwhile, the internal volume of the fluid control area (210) and the amount of liquid medicine delivered once through the microneedle (400) are not limited to being set to be the same. For example, the fluid control area (210) may contain more liquid medicine than the amount delivered once, and a preset unit amount may be supplied during a single liquid medicine delivery process. Additionally, it may be configured so that an accumulated amount of liquid medicine greater than the internal volume of the fluid control area (210) is delivered through multiple flow characteristic controls or liquid medicine supply cycles. Accordingly, the internal volume of the fluid control area (210) and the amount of liquid medicine delivered once may be set independently of each other depending on the type of liquid medicine, the number of microneedle (400), and treatment conditions.

[0197] However, the area of ​​the fluid control region (210), the gap between the interfaces, and the internal volume may vary depending on the supply amount of the liquid, the viscosity and rheological properties of the liquid, the required shear conditions, the number of microneedles (400), and the size of the medical device, and the present invention is not limited to the above numerical range. The shear membrane may repeatedly move or deform in the plane direction with respect to the lower interface to impart mechanical shear to the liquid located in the fluid control region (210).

[0198] The cartridge or tip may be provided with an inlet for introducing a liquid medicine from the outside, and the liquid medicine introduced through the inlet may be supplied to a fluid control area (210). A flow path (300) is connected to the downstream side of the fluid control area (210), and the liquid medicine with controlled flow characteristics may move toward the microneedle (400) through the flow path (300).

[0199] The placement positions of the inlet and flow path sections (300) are not limited to a specific direction and can be set in various ways depending on the shape of the cartridge, the structure of the fluid control area (210), and the movement path of the liquid medicine.

[0200] Accordingly, the driving force of the driving source provided in the main body of the medical device can be transmitted to the shear membrane through the driving coupling part.

[0201] Accordingly, the driving source can be provided on the side of the medical device body and used repeatedly while replacing the part including the fluid control area (210) in contact with the drug solution, the fluid path (300), the drug delivery path (310), and the microneedle (400) after use.

[0202] Meanwhile, when a plurality of microneedles (400) are provided, the replaceable cartridge or tip may further be provided with a distribution section for distributing the liquid medicine between the fluid control area (210) and the plurality of microneedles (400). The distribution section may be configured to distribute the liquid medicine discharged from the fluid control area (210) to a plurality of branching passages (320) corresponding to each of the plurality of microneedles (400).

[0203] Additionally, the above-mentioned replaceable cartridge or tip may be provided with an outflow control unit for controlling the outflow of the drug solution downstream of the fluid control area (210). The outflow control unit may be configured to suppress the outflow of the drug solution from the fluid control area (210) to the drug delivery path (310) while mechanical shear is applied to the drug solution by a shear generation structure, and to discharge the drug solution to the drug delivery path (310) after the mechanical shear is terminated.

[0205] In addition, in one embodiment, a negative pressure section for applying negative pressure to the skin tissue may be further provided in at least a portion of the injection area where a plurality of microneedles (400) are inserted into the skin tissue.

[0206] The above-mentioned negative pressure portion may include a suction area formed to surround at least a portion of the area where the microneedle (400) is placed, and may fix the position of the skin tissue or flatten the skin surface by adsorbing the skin tissue toward the device, and suppress the displacement of the skin tissue during the insertion process of the microneedle (400).

[0207] The control unit (600) may control the supply of a drug solution through a plurality of microneedles (400) after a preset negative pressure is formed or after the adsorption state of the skin tissue or the contact state between the skin tissue and the medical device is secured.

[0208] In addition, a drug solution with controlled flow characteristics can be divided and delivered to multiple locations within the skin tissue through a plurality of microneedles (400) while the skin tissue is adsorbed or flattened by negative pressure.

[0210] The above drug supply unit (500) may be configured to supply the drug liquid contained in the drug liquid storage unit (100) to the fluid control unit (200), the flow path unit (300), and the microneedle (400).

[0211] The above drug supply unit (500) can control at least one of the supply pressure, flow rate, or supply amount of the drug solution and may be configured to repeatedly supply a fixed amount of drug solution as needed. The above drug supply unit (500) may include, for example, a piston, a plunger, a syringe pump, a diaphragm pump, a pressure pump, a metering pump, or a driving means capable of moving the drug solution. However, the specific form of the drug supply unit (500) is not limited thereto.

[0212] The above drug supply unit (500) can operate under the control of the control unit (600), supply the drug from the drug storage unit (100) to the fluid control area (210), and move the drug with controlled flow characteristics from the fluid control area (210) to the microneedle (400) side through the flow path unit (300). At this time, the operating time of the drug supply unit (500) can be linked to the operating time of the flow characteristic control unit (220).

[0213] In one embodiment, mechanical shearing is applied to the liquid medicine for a preset time by the flow characteristic control unit (220), and then the mechanical shearing is terminated. After the shearing is terminated, the drug supply unit (500) can be operated within a time interval during which the reduced flow resistance is maintained at least partially. In such batch operation, the flow characteristics of the liquid medicine are first controlled in the fluid control area (210), and then the liquid medicine is supplied to the microneedle (400), thereby allowing the timing of the liquid medicine supply to be set by considering the recovery behavior of the flow characteristics after the shearing is terminated. For example, after applying mechanical shearing to the liquid medicine located in the fluid control area (210) for a preset time, the drug supply unit (500) can be operated to supply the liquid medicine to the microneedle (400) while the flow resistance of the liquid medicine is reduced.

[0214] In another embodiment, the application of mechanical shear and the supply of the liquid can overlap for at least some time intervals. For example, while continuously applying mechanical shear to the liquid, a portion of the liquid with reduced flow resistance can be supplied to the flow path (300) continuously or intermittently, and accordingly, the control of flow characteristics and the delivery of the liquid can be performed simultaneously or partially overlapping.

[0215] In another embodiment, the liquid medicine may receive mechanical flow action while continuously passing through a fluid control area (210) during the process of moving from the liquid medicine storage unit (100) to the microneedle (400). In this case, the fluid control area (210) is not limited to a separate batch chamber, but may be formed in a flow path, pump room, valve area, distribution area, or at least part of a needle hub, and the movement of the liquid medicine and control of its flow characteristics may be performed continuously.

[0216] Such overlapping or continuous operation can be applied as an optional mode of operation distinct from the batch type embodiment supplied within a set time interval after the end of the shear.

[0217] Additionally, to control the flow characteristics of the liquid medicine, at least a portion of the liquid medicine may be reciprocated within the fluid control area (210), repeatedly moved between the fluid control area (210) and an adjacent flow path, or recirculated along a set circulation path. During this reciprocating or recirculation process, a relative flow or velocity gradient may be formed within the liquid medicine by the repeated opening and closing of the valve, pressure fluctuations, changes in the cross-section of the flow path, changes in the flow direction, or movement of the driving member, and accordingly, the viscosity or flow resistance of the liquid medicine may be temporarily reduced.

[0218] For example, the control unit (600) can first operate the flow characteristic control unit (220) before the drug solution is supplied to the microneedle (400) to apply mechanical shear to the drug solution located in the fluid control area (210), and then operate the drug supply unit (500) in a state where the flow resistance of the drug solution is reduced.

[0220] In addition, as described above, since the drug solution can maintain a reduced flow resistance state for at least a certain period of time even after the mechanical shearing is finished, the control unit (600) can operate the drug supply unit (500) within the time interval during which the reduced flow resistance is maintained for at least a certain period.

[0221] In one embodiment, the control unit (600) may control the operation of the drug supply unit (500) to begin within 60 seconds after the end of mechanical shearing, and if a shorter supply start time is required, it may control the supply of the drug solution to begin within 30 seconds, within 10 seconds, or within 5 seconds. Mechanical shearing may be applied for a period of less than 10 seconds to reduce the flow resistance of the drug solution within a short period, and more specifically, for 1 to 3 seconds. In this case, the control unit (600) may control the supply of the drug solution to occur while at least some of the reduced flow resistance of the drug solution is maintained after the end of mechanical shearing, for example, the supply of the drug solution may begin within 60 seconds after the end of shearing. Accordingly, while shortening the pretreatment time for controlling the flow characteristics of the drug solution, a time interval can be secured in which the reduced flow resistance state after the end of shearing can be utilized for drug solution delivery.

[0222] The above time range does not imply that the viscosity or flow resistance of the liquid is fully recovered within the specified time, but rather represents an example of a supply initiation condition for utilizing a state in which the viscosity or flow resistance reduced by mechanical shear is maintained at least partially for liquid delivery.

[0223] In addition, the supply of the chemical solution may be initiated substantially simultaneously with the termination of mechanical shearing, and, if necessary, the application of mechanical shearing and the supply of the chemical solution may be controlled to overlap in some time intervals before and after the termination of mechanical shearing.

[0224] Accordingly, the drug supply unit (500) can supply a drug liquid with a relatively low flow resistance to the flow path unit (300) and the plurality of microneedles (400).

[0225] The above drug supply unit (500) may continuously generate the supply pressure or flow rate of the drug liquid as needed, or may supply the drug liquid by dividing it into multiple unit supply operations.

[0226] For example, the system may be operated repeatedly by supplying a preset amount of liquid medicine during one liquid medicine delivery cycle, then pausing the supply, and then operating the flow characteristic control unit (220) again and supplying the next unit amount of liquid medicine.

[0227] This repetitive supply method allows the liquid to be supplied after readjusting its flow characteristics at each delivery cycle, even if the flow characteristics of the liquid recover over time.

[0228] In addition, the operating conditions of the drug supply unit (500) can be adjusted according to the type of drug solution, viscosity, operating conditions of the fluid control unit (200), fluid resistance of the flow path unit (300), number of microneedles (400), and target drug solution delivery amount.

[0230] Meanwhile, at the stage where the supply of the drug solution ends, a certain amount of drug solution may remain inside the fluid control area (210), the flow path (300), or the drug delivery path (310).

[0231] Here, the geometric internal volume that must be filled with the liquid by the structure of the liquid delivery path or fluid space and the amount of residual liquid actually remaining inside after the supply or discharge of the liquid is finished can be distinguished from each other. The former structural priming volume can be determined by the shape and volume of the fluid control area (210), the flow path (300), and the drug delivery path (310), and the latter amount of residual liquid can vary depending on the viscosity and flow characteristics of the liquid, adhesion characteristics with the inner wall, the location of the discharge port, the shape of the flow path, supply conditions, and the residual liquid discharge process.

[0232] To discharge such residual liquid, a deformable interface may be provided in at least a part of the fluid control area (210) and the flow path (300).

[0233] As shown in FIG. 5, the deformable interface can be sequentially deformed from the fluid control area (210) side toward the microneedle (400) side during the drug solution delivery termination stage.

[0234] As the above boundary surface is sequentially deformed, the internal volume of at least a portion of the fluid control area (210), the flow path (300), and the drug delivery path (310) may be reduced, and accordingly, the drug liquid remaining inside may be moved toward the microneedle (400).

[0235] That is, as shown in FIG. 5 (a), some of the drug solution may remain inside the fluid control area (210), the flow path (300), or the drug delivery path (310) immediately before the end of drug solution delivery.

[0236] Subsequently, as shown in FIG. 5(b), when the deformable interface is sequentially deformed from the fluid control area (210) side toward the microneedle (400) side, the internal volume is reduced stepwise due to the deformation of the interface and the residual liquid can move downstream.

[0237] And as illustrated in FIG. 5(c), when the sequential deformation is completed, the residual drug liquid inside the fluid control area (210) and the flow path (300) can be moved along the drug delivery path (310) toward the microneedle (400) and discharged. The deformable interface may be formed as an elastic membrane, a flexible wall, a diaphragm, or a similar structure deformable by an external force.

[0238] The deformation method of the above-mentioned deformable interface is not limited to a specific method and can be achieved by mechanical pressurization, fluid pressure, pneumatic pressure, direct displacement by an actuator, or a combination thereof.

[0239] Additionally, the deformable boundary surface does not necessarily need to be formed continuously over the entire section of the fluid control area (210) and the flow path section (300), and may be divided and provided in one or more sections necessary for the movement of residual liquid.

[0240] In this way, by reducing the internal volume at the end of the liquid delivery stage and moving the residual liquid to the microneedle (400), the amount of liquid remaining inside the fluid control section (200) and the flow path section (300) can be reduced.

[0241] In addition, to reduce the amount of residual liquid, at least one of the internal shape of the fluid control area (210) or the flow path (300), the location of the discharge port, the slope of the flow path, the surface characteristics of the inner wall in contact with the liquid, and the flow characteristic control conditions may be adjusted. Accordingly, even without necessarily reducing the structural priming volume itself, it can be configured to reduce the amount of liquid actually remaining inside after liquid delivery or to improve the recovery rate relative to the amount injected.

[0243] The above control unit (600) can control the operation of the drug supply unit (500) and the flow characteristic control unit (220). The control unit (600) can operate the flow characteristic control unit (220) before the drug solution is supplied to the microneedle (400) to apply mechanical shear to the drug solution located in the fluid control area (210), and operate the drug supply unit (500) while the flow resistance of the drug solution is reduced.

[0244] Additionally, the control unit (600) can operate the drug supply unit (500) within a time interval during which the reduced flow resistance of the drug liquid is maintained for at least a portion after the flow resistance of the drug liquid has been reduced.

[0245] The above control unit (600) can control at least one of the unilateral amplitude, repetition rate, shear application time, or number of repetitions of the flow characteristic control unit (220), and can control at least one of the supply pressure, flow rate, supply time, or supply amount of the drug supply unit (500).

[0246] Accordingly, the control unit (600) can control the flow characteristic control conditions and the liquid supply conditions according to the type of liquid, the shape of the fluid control area (210), the fluid resistance of the flow path (300), the number of microneedles (400), and the target liquid delivery amount.

[0248] Meanwhile, the medical device for delivering a drug solution according to the present invention may further include a flow state detection unit (800) for detecting information related to the flow state or supply state of the drug solution.

[0249] The above flow state detection unit (800) can detect state information related to at least one of the flow characteristic control unit (220), drug supply unit (500), fluid control area (210), flow path unit (300), or drug delivery path (310).

[0250] The above state information may include, for example, at least one of the pressure, flow rate, flow velocity, discharge pressure of the drug solution, the driving load of the drug supply unit (500), the operating state of the flow characteristic control unit (220), or the flow state of the drug solution estimated from these.

[0251] The control unit (600) can adjust at least one of the operating conditions of the flow characteristic control unit (220) or the operating conditions of the drug supply unit (500) based on the state information detected by the flow state detection unit (800).

[0252] For example, if the flow rate of the liquid medicine is detected to be lower than a preset range or the pressure for supplying the liquid medicine is increased, the control unit (600) can adjust the mechanical shear conditions applied to the liquid medicine by changing at least one of the unilateral amplitude, repetition rate, shear application time, or number of repetitions.

[0253] Conversely, when the flow rate of the liquid medicine reaches the target range, the operation of the flow characteristic control unit (220) may be reduced or terminated and the drug supply unit (500) may be operated.

[0254] Therefore, the present invention is not limited to repeatedly applying only a single fixed shear condition set in advance, and the flow characteristic control conditions and the chemical supply conditions can be adjusted according to the actual flow state of the chemical solution or the operating state of the device.

[0256] In addition, the medical device for delivering liquid medicine according to the present invention may further include an electric energy delivery unit (700) for applying electric energy to skin tissue.

[0257] As illustrated in FIG. 6, the electric energy delivery unit (700) can apply electric energy to the skin tissue under the control of the control unit (600) and can operate at least one time before, during, or after the liquid medicine is delivered to the skin tissue.

[0258] The above electrical energy may be applied in a form that can change the electrical state of the skin tissue or assist in the movement or distribution of the drug solution within the skin tissue.

[0259] For example, the electric energy delivery unit (700) may be configured to implement at least one of electroporation, iontophoresis, electrophoresis, electroosmosis, or electric stimulation.

[0260] However, the type, waveform, voltage, current, frequency, and application time of the electrical energy applied by the electrical energy delivery unit (700) can be set in various ways depending on the condition of the skin tissue, the type of liquid to be delivered, and the required drug delivery conditions.

[0261] The above control unit (600) can control the operation of the flow characteristic control unit (220), the operation of the drug supply unit (500), and the operation of the electric energy transfer unit (700) in a timely manner.

[0262] For example, electrical energy can be applied to the skin tissue first, then mechanical shear can be applied to the drug solution, and then the drug solution can be supplied to the microneedle (400) in a state where the flow resistance of the drug solution is reduced.

[0263] Alternatively, the flow characteristics of the drug solution may be adjusted first, then electrical energy may be applied to the skin tissue, and then the drug solution may be supplied.

[0264] In addition, the application of electrical energy and the supply of the chemical solution can be controlled to overlap for at least some time intervals.

[0265] Therefore, the specific sequence of flow characteristic control, drug solution supply, and electrical energy application is not limited to a single method and can be set according to the purpose of the procedure or the characteristics of the drug solution.

[0267] Meanwhile, the medical device for delivering a liquid drug according to the present invention may further include a bio-information sensing unit (900) for detecting the electrical characteristics of skin tissue.

[0268] As illustrated in FIG. 6, the bio-information sensing unit (900) can detect at least one of the impedance, resistance, voltage, current, phase, or related electrical characteristics of the skin tissue.

[0269] The control unit (600) can determine whether the electrical transmission state of the skin tissue has reached a preset target state or target range based on the detection result of the bio-information detection unit (900).

[0270] For example, if the impedance or resistance of the skin tissue satisfies a preset condition after electrical energy is applied to the skin tissue by the electrical energy delivery unit (700), the control unit (600) can determine that the skin tissue has reached a target permeability state suitable for drug delivery.

[0271] When the control unit (600) determines that the skin tissue has reached the target permeability state, it can operate the drug supply unit (500) within a preset time interval to supply the drug solution to the plurality of microneedles (400).

[0272] At this time, the control unit (600) can operate the flow characteristic control unit (220) to allow the drug solution with reduced flow resistance to be delivered to the skin tissue within the time interval.

[0273] Accordingly, the drug solution can be supplied by temporally linking the state in which the flow characteristics of the drug solution itself are controlled with the state in which the electrical state of the skin tissue is suitable for drug delivery.

[0275] Additionally, when a plurality of microneedles (400) are divided into a plurality of drug delivery groups (410), the electric energy delivery unit (700) may include a plurality of electrodes (710) for applying electric energy to skin tissue.

[0276] The plurality of electrodes (710) may be divided into a plurality of electrode groups (720), and each electrode group (720) may include one or more electrodes (710). As shown in FIG. 7, the plurality of electrode groups (720) may be divided, for example, into G1, G2, G3, and G4, and each electrode group (720) may be configured to apply electrical energy to a corresponding area of ​​skin tissue.

[0277] The plurality of electrode groups (720) may each be configured to correspond to a plurality of drug delivery groups (410). Here, the correspondence between each electrode group (720) and the drug delivery group (410) does not necessarily mean that one electrode and one microneedle correspond individually, but rather that one or more electrodes and one or more microneedles correspond as a group unit based on one skin treatment area.

[0278] For example, when electrical energy is applied to an area of ​​skin tissue corresponding to the first electrode group, and it is determined that the area has reached a target permeability state based on the detection result of the bio-information sensing unit (900), the control unit (600) can select a first drug delivery group corresponding to the first electrode group.

[0279] The control unit (600) can control the drug supply unit (500) so that the drug solution is supplied to the selected drug delivery group (410), and accordingly, the drug solution can be delivered to the corresponding skin tissue through the microneedle (400) included in the drug delivery group (410).

[0280] In addition, while sequentially determining the condition of the skin tissue corresponding to the multiple electrode groups (720), the drug solution may be sequentially supplied to the drug delivery group (410) corresponding to the area that has reached the target permeability state.

[0281] Accordingly, the location or timing of drug supply can be selectively controlled in response to the electrical state of each region of the skin tissue.

[0282] This control is not limited to a method of supplying the drug solution collectively under the same conditions throughout the entire skin tissue, but can be achieved by selecting multiple drug delivery groups (410) individually or in multiple units according to the condition of each region of the skin tissue to supply the drug solution.

[0284] A method for delivering a drug solution containing a polymer into skin tissue using a drug solution delivery medical device having the above-described configuration can be performed as follows.

[0285] First, the liquid medicine contained in the liquid medicine storage unit (100) can be supplied to the fluid control area (210) by the operation of the drug supply unit (500).

[0286] When the liquid medicine is located in the fluid control area (210), the control unit (600) can operate the flow characteristic control unit (220) before the liquid medicine is supplied to the microneedle (400) to apply mechanical shear to the liquid medicine.

[0287] The viscosity or flow resistance of the liquid may be temporarily reduced by the application of the above mechanical shear, and the liquid with controlled flow characteristics may move to a flow path (300) provided on the downstream side of the fluid control area (210).

[0288] The drug solution supplied to the Euro section (300) can be supplied to the microneedle (400) side through the drug delivery route (310).

[0290] Afterwards, the drug solution supplied to the microneedle (400) can be delivered into the skin tissue.

[0291] In this way, by applying mechanical shear in the fluid control area (210) provided on the upstream side of the microneedle (400) before supplying the drug solution to the microneedle (400), the drug solution with reduced flow resistance can be delivered to the skin tissue through the drug delivery path (310).

[0292] In the process of applying the above mechanical shear, the flow characteristic control unit (220) can move at least one boundary surface forming the fluid control area (210) relative to another boundary surface.

[0293] At this time, the microneedle (400) can be supported independently of the relative movement of the interface. Therefore, even when repetitive displacement occurs at the interface to control flow characteristics, the same repetitive motion can be suppressed from being directly transmitted to the microneedle (400) itself.

[0294] Additionally, the control unit (600) can adjust at least one of the unilateral amplitude (A), the repetition rate of relative displacement, the application time of mechanical shear, and the number of repetitions in correspondence with the gap (h) between the boundary surfaces forming the fluid control area (210).

[0295] For example, if the gap (h) between the interfaces is changed, the shear conditions applied to the chemical solution can be changed by adjusting the one-sided amplitude (A) or the repetition rate, and the shear application time or the number of repetitions can be adjusted according to the rheological properties of the chemical solution or the required degree of flow resistance reduction.

[0296] Accordingly, mechanical shear conditions can be set in response to the structure of the fluid control area (210) and the characteristics of the liquid, without being limited to a specific frequency or a single displacement condition.

[0298] Meanwhile, as mentioned above, the viscosity or flow resistance of the liquid reduced by mechanical shear can be recovered over time after the shear is completed.

[0299] Accordingly, the control unit (600) can operate the drug supply unit (500) within a time interval during which the reduced flow resistance is maintained at least partially after the flow resistance of the drug liquid is reduced by the application of mechanical shear.

[0300] For example, within the drug solution supply time interval (Td) shown in FIG. 4, the drug solution can be supplied to the flow path (300) and supplied to the multiple microneedles (400) via the multiple drug delivery paths (310).

[0301] Accordingly, the drug solution can be moved to the multiple microchannels and microneedles (400) before the flow resistance of the drug solution increases again.

[0302] In addition, if the supply amount of the liquid medicine is set to multiple unit amounts, the flow characteristic control unit (220) may be operated before supplying each unit amount to apply mechanical shear to the liquid medicine, and then the process of supplying the corresponding unit amount may be repeated.

[0303] According to this method, even if the flow characteristics of the chemical solution recover over time, the chemical solution can be delivered with the flow resistance reduced again during each supply cycle.

[0305] Meanwhile, when a preset amount of drug solution is supplied or the termination condition for drug solution delivery is satisfied, a residual drug solution discharge process can be performed to move the drug solution remaining inside the fluid control area (210), the flow path (300), or the drug delivery path (310) toward the microneedle (400).

[0306] As illustrated in FIG. 5, in the residual liquid discharge process, a deformable boundary surface provided in at least a part of the fluid control area (210) and the flow path (300) can be sequentially deformed from the fluid control area (210) side toward the microneedle (400) side.

[0307] As the volume of the internal space where the drug solution is located decreases according to the sequential deformation of the above boundary surface, the drug solution remaining inside can be moved toward the microneedle (400) along the drug delivery path (310).

[0308] This residual drug solution discharge process is not limited to being performed only after the supply of the drug solution has been completely terminated, but may also be performed at the end of the supply phase of a preset single dose or unit supply amount.

[0310] In addition, the drug solution delivery method according to the present invention may include a process of applying electrical energy to skin tissue as needed.

[0311] As illustrated in FIG. 6, the control unit (600) can apply electrical energy to the skin tissue by operating the electrical energy transfer unit (700) and can detect the electrical characteristics of the skin tissue through the bio-information sensing unit (900).

[0312] The above bio-information sensing unit (900) can detect at least one of the impedance, resistance, voltage, current, phase, or related electrical characteristics of the skin tissue, and the control unit (600) can determine whether the skin tissue has reached a preset target penetration state based on the detection result.

[0313] When the control unit (600) determines that the skin tissue has reached a target permeability state, it can control the drug supply unit (500) so that a drug solution with controlled flow characteristics is delivered to the skin tissue through a plurality of microneedles (400) within a preset time interval.

[0314] Accordingly, the process of applying electrical energy to the skin tissue, the process of detecting the electrical properties of the skin tissue, the process of applying mechanical shear to the drug solution, and the process of supplying the drug solution to the skin tissue can be performed in a time-coordinated manner.

[0315] The specific sequence of each of the above processes is not limited to a single method. For example, mechanical shear may be applied to the liquid and the liquid supplied after applying electrical energy, or electrical energy may be applied and the liquid supplied after applying mechanical shear to the liquid. In addition, at least a portion of the application of electrical energy and the supply of the liquid may overlap in time.

[0316] When a plurality of electrode groups (720) and a plurality of drug delivery groups (410) are configured to correspond, the target for supplying the drug solution may be selected according to the condition of each region of the skin tissue.

[0317] For example, as shown in FIG. 7, when it is determined that an area of ​​skin tissue corresponding to a specific electrode group (720) has reached a target permeability state, the control unit (600) can select a drug delivery group (410) corresponding to the electrode group (720) and control the drug supply unit (500) so that a drug solution is supplied to the selected drug delivery group (410).

[0318] Accordingly, the drug solution can be delivered not only by supplying the drug solution to multiple skin treatment areas collectively at the same time, but also by selectively or sequentially operating the drug delivery group (410) in response to the condition of each skin treatment area.

[0320] Hereinafter, an experimental example will be described to confirm the rheological characteristics in which, when mechanical shear is applied to a chemical solution containing a polymer by the operation of the fluid control unit (200) according to the present invention, the viscosity or flow resistance of the chemical solution is temporarily reduced and then recovered over time after the shear is terminated.

[0321] In this experiment, the change in viscosity of a composition containing polynucleotide (PN) under mechanical shear conditions was measured, and the viscosity recovery behavior after the shearing was completed was confirmed.

[0322] For the experiment, a composition containing polynucleotide (PN) was used, and measurements were taken using a rotary rheometer. PP25 parallel plates were used for the measurements, and the measurement gap was set to 1 mm and the measurement temperature to approximately 31.4°C.

[0323] Each test was performed to include a low-shear section before shear application, a high-shear section at a set shear rate, an initial recovery section immediately after shear termination, and a long-term recovery section. The test conditions are as shown in Table 1 below.

[0324] test pre-shed conditions High shear condition Conditions immediately after shearing Long-term recovery conditions A1 0.01s -1 , 10 seconds 100s -1 , 10 seconds 0.01s -1 , 5 seconds 0.01s -1 , 300 seconds A2 0.01s -1 , 10 seconds 500s -1 , 2 seconds 0.01s -1 , 5 seconds 0.01s -1 , 300 seconds A3 0.01s -1 , 30 seconds 1000s -1 , 1 second 0.01s -1 , 5 seconds 0.01s -1 , 300 seconds A4 0.01s -1 , 30 seconds 1000s -1 , 2 seconds 0.01s -1 , 5 seconds 0.01s -1 , 900 seconds A5 0.01s -1 , 30 seconds 1000s -1 , 2 seconds 0.1s -1 , 5 seconds 0.1s -1 , 900 seconds A6 0.1s -1 , 30 seconds 1000s -1 , 2 seconds 0.1s -1 , 5 seconds 0.1s -1 , 900 seconds

[0326] For A1 to A3, the shear rate and shear time were set so that the cumulative deformation in the high-shear region was the same. Specifically, A1 was 100s -1 10 seconds at, A2 is 500s -1 2 seconds at, A3 is 1000s -1 High shear was applied for 1 second.

[0327] In each of the above tests, the comparison criterion before shear was set to the average viscosity of the first 10-second interval common to all three tests. The measurement results are as shown in Table 2 below.

[0328] test High shear condition Average viscosity (mPa·s) for the first 10 seconds before shearing High-shear end viscosity (mPa·s) Viscosity (mPa·s) 5 seconds after shearing ends recovery rate A1 100s -1 , 10 seconds 17,533.08 166.110 13,796.0 78.7% A2 500s -1 , 2 seconds 24,032.58 89.231 10,797.0 44.9% A3 1000s -1 , 1 second 17,723.05 48.603 8,629.5 48.7%

[0330] As shown in Table 2, the high-shear end viscosity was measured to be 166.110 mPa·s at A1, 89.231 mPa·s at A2, and 48.603 mPa·s at A3.

[0331] Accordingly, it was confirmed that even under the same cumulative deformation conditions, the viscosity at the end of the high-shear point tends to decrease as the shear rate increases.

[0332] In addition, recovery behavior was observed in which viscosity increased again after the shearing process ended. However, since the measurement time before shearing and the recovery measurement conditions in each test may not be exactly the same, it is not necessary to interpret the difference in recovery rates between A1 and A3 solely as an effect of the shear rate.

[0334] Meanwhile, 1000s -1 To determine the effect of shear time on the shear rate, the results of A3 and A4 were compared. The results are shown in Table 3 below.

[0335] item A3 A4 High shear condition 1000s -1 , 1 second 1000s -1 , 2 seconds Total average viscosity before shear (mPa·s) 53,865.15 68,806.80 High-shear endpoint viscosity (mPa·s) 48.603 46.294

[0337] The high-shear endpoint viscosities in A3 and A4 were 48.603 mPa·s and 46.294 mPa·s, respectively, indicating similar levels. Therefore, under these experimental conditions, 1000s -1 When a shear rate is applied, a significant decrease in viscosity can occur with only a shear time of about 1 second, and even if the shear time is increased to 2 seconds, the additional decrease in high-shear end viscosity is not relatively large.

[0338] Meanwhile, when comparing the recovery behavior after the end of shearing, A4, which was subjected to shearing for 2 seconds, showed a tendency for the reduced viscosity state to be maintained for a longer period or for the recovery of viscosity to be delayed compared to A3, which was subjected to shearing for 1 second. Therefore, the condition of applying shearing for 2 seconds can be understood as having an effect on the time during which the reduced rheological state is maintained after the end of shearing, rather than being intended to significantly further reduce the minimum viscosity at the end of high shearing.

[0339] However, in the low-shear measurement section immediately after the end of the shearing of A4, the torque acting on the rheometer is lower than the stable measurement range, so some measurement values ​​may appear unstable; therefore, it is not desirable to quantitatively determine the recovery behavior based on a single measurement value immediately after the end of the shearing. Accordingly, the recovery behavior of A3 and A4 can be interpreted together with the results of the supplementary test and long-term recovery test of A5 and A6 described later.

[0340] 1000s -1 To verify the repeatability of viscosity reduction under conditions where a shear rate was applied for 2 seconds, the results of A4 to A6 were compared. The results are shown in Table 4 below.

[0341] test High-shear endpoint viscosity (mPa·s) A4 46.294 A5 47.842 A6 48.988 average 47.708 Sample standard deviation 1.352 Coefficient of variation About 2.8%

[0343] As shown in Table 4, 1000s -1 The high-shear end viscosity of A4 to A6, to which a shear rate was applied for 2 seconds, was measured to be in the range of 46.294 mPa·s to 48.988 mPa·s, with an average of 47.708 mPa·s and a coefficient of variation of approximately 2.8%.

[0344] Accordingly, under the above conditions, it was possible to confirm a tendency for the viscosity of the drug solution to repeatedly decrease to a similar level.

[0345] In addition, the A6 test results were analyzed to verify the long-term recovery behavior of viscosity after the end of shearing.

[0346] In A6, the low-shear measurement conditions before and after shear were both 0.1s -1 It was set to , and the average viscosity for 30 measurements before shear was found to be 32,913.59 mPa·s.

[0347] Since unstable measurements due to equipment deceleration and torque switching may be included during the approximately 5 seconds immediately following the end of shearing, the long-term viscosity recovery behavior was analyzed based on measurements taken approximately 10 seconds after the end of shearing. The measurement results are shown in Table 5 below.

[0348] Time elapsed since the end of the shear Viscosity (mPa·s) Compared to the average before shear 10 seconds 405.2 1.23% 30 seconds 1,222.6 3.71% 60 seconds 2,394.2 7.27% 120 seconds 4,450.0 13.52% 180 seconds 6,823.8 20.73% 300 seconds 10,121.0 30.75% 600 seconds 21,604.0 65.64% 900 seconds 26,992.0 82.01% 910 seconds 27,128.0 82.42%

[0350] As shown in Table 5, in the A6 test, recovery behavior was confirmed in which the viscosity of the liquid continued to increase over time after the mechanical shear was completed.

[0351] Specifically, the viscosity about 300 seconds after the end of shearing was about 30.75% of the average viscosity before shearing, about 65.64% after about 600 seconds, and about 82.01% after about 900 seconds.

[0352] Accordingly, it was confirmed that the chemical solution used in this experiment exhibited rheological characteristics in which the viscosity temporarily decreased significantly upon the application of high shear, and then increased again over time after the mechanical shear ended.

[0353] These experimental results support the fact that, as previously explained with reference to Fig. 4, the flow resistance of the liquid is temporarily reduced by the application of mechanical shearing by the flow characteristic control unit (220), and after the shearing is finished, the reduced flow resistance is maintained for at least a certain period of time and then gradually recovered.

[0354] Accordingly, the control unit (600) can control the drug supply unit (500) to operate within a time interval in which the reduced flow resistance is maintained at least partially, by considering the recovery behavior of the viscosity or flow resistance set according to the type of drug solution and shear conditions.

[0355] However, the above experimental results are one example obtained under specific PN-containing compositions and specific measurement conditions, and the degree of viscosity reduction and recovery speed may vary depending on the composition of the liquid, the type and concentration of the polymer, temperature, the shape of the fluid control area (210), the shear rate and the shear application time, etc.

[0356] In addition, the long-term recovery test of the above A6 is 0.1s -1 Since the results were measured while continuously applying low shear, it does not mean that the drug solution in a completely stopped state or the drug solution after being delivered into the skin tissue recovers at the same rate.

[0358] Meanwhile, in order to evaluate the characteristics of the chemical solution and the delivery performance according to the flow characteristic control conditions of the present invention, the following additional evaluations may be performed as necessary. The evaluation methods below represent exemplary methods for verifying the technical characteristics of the present invention and do not imply that specific evaluation results have already been achieved.

[0359] First, changes in the molecular weight and molecular weight distribution of the polymer before and after the application of mechanical shear can be evaluated. To this end, an untreated chemical solution and a chemical solution treated under set flow characteristic control conditions are prepared, and at least one of the weight-average molecular weight (Mw), number-average molecular weight (Mn), polydispersity index (PDI), molecular weight distribution curve (MWD), and low molecular weight fraction can be compared using at least one analytical method among GPC, SEC, SEC-MALS, and AF4-MALS. If necessary, the chemical solution passed through the microneedle can be set as a separate control group. Each sample can be compared by setting the storage time, temperature, dilution conditions, and analysis conditions to be identical or corresponding.

[0360] Based on the above evaluation results, flow characteristic control conditions can be selected to reduce the flow resistance of the chemical solution while suppressing irreversible changes occurring in the molecular weight distribution of the polymer. However, the specific degree of maintenance of the molecular weight or molecular weight distribution may vary depending on the type, concentration, and shear conditions of the polymer used.

[0362] Additionally, the uniformity of drug dispensing through multiple microneedles (400) can be evaluated. For example, when using nine hollow microneedles (400) arranged in a 3×3 array, the mass or volume of the drug dispensing from each microneedle (400) can be measured individually. From the measured values, the uniformity of dispensing can be evaluated by calculating at least one of the average dispensing amount of all microneedles, the standard deviation, the coefficient of variation (CV), the maximum dispensing amount, the minimum dispensing amount, and the deviation from the average dispensing amount of each microneedle.

[0363] Such evaluation can be performed before and after the application of the fluid resistance correction unit, before and after the control of flow characteristics, or between different flow characteristic control conditions, and between the comparison subjects, the amount of drug solution injected, the driving conditions of the drug supply unit (500), and the specifications of the microneedle (400) can be set to be identical or corresponding.

[0364] In addition, the amount of liquid remaining inside the medical device or cartridge after liquid delivery can be evaluated. To this end, the initial injection amount and the actual discharge amount of the liquid are measured, and at least one of the amount of liquid remaining after discharge and the recovery rate relative to the injection amount can be calculated by utilizing the difference in cartridge weight before and after discharge, or by recovery or washing analysis of the liquid remaining inside. If necessary, the structural priming volume corresponding to the geometric volume of the fluid space to be filled with the liquid and the amount of liquid remaining inside after liquid delivery can be evaluated separately.

[0366] Optimal embodiments have been disclosed in the drawings and specification. Specific terms have been used herein, but are used only for the purpose of describing the invention and are not intended to limit the meaning or the scope of the invention as described in the claims. Therefore, those skilled in the art will understand that various modifications and equivalent alternative embodiments are possible therefrom. Accordingly, the true technical scope of protection of the invention should be determined by the technical spirit of the appended claims. Explanation of the symbols

[0367] 100: Liquid storage unit 200: Fluid control unit 210: Fluid control area 220: Flow characteristic control section 300: Eurobu 310: Drug delivery route 320: Quarterly Euro 400: Microneedle 410: Drug delivery group 500: Drug supply unit 600: Control unit 700: Electric energy transfer unit 710: Electrode 720: Electrode group 800: Fluid state detection unit 900: Biometric information detection unit

Claims

Claim 1 A drug delivery medical device for delivering a drug solution containing a polymer into skin tissue, comprising: a drug solution storage unit for receiving the drug solution; a fluid control unit provided downstream of the drug solution storage unit and including a fluid control region through which the drug solution passes and a flow characteristic control unit that applies mechanical shear to the drug solution located in the fluid control region to temporarily reduce the flow resistance of the drug solution; a flow path unit provided downstream of the fluid control region and moving the drug solution that has passed through the fluid control region to at least one drug delivery path; at least one microneedle provided to be insertable into skin tissue and delivering the drug solution supplied through the at least one drug delivery path to the skin tissue; and a drug supply unit that supplies the drug solution from the drug solution storage unit through the fluid control region and the flow path unit to the at least one microneedle. A rheological pretreatment-based polymer drug delivery medical device comprising: a control unit that controls the operation of the flow characteristic control unit and the drug supply unit; wherein the control unit operates the flow characteristic control unit before the drug solution is supplied to the at least one microneedle to impart mechanical shear to the drug solution in the fluid control region, and controls the drug solution, whose flow resistance is reduced by the mechanical shear, to be supplied to the at least one microneedle through the flow channel. Claim 2 A rheological pretreatment-based polymer drug delivery medical device according to claim 1, wherein the flow characteristic control unit is configured to impart mechanical shear to the drug located in the fluid control region by causing at least one interface forming the fluid control region to be displaced relative to another interface, and the at least one microneedle is supported independently of the relative displacement of the interface. Claim 3 A rheological pretreatment-based polymer drug delivery medical device according to claim 2, wherein the control unit is configured to control mechanical shear applied to the drug solution by controlling at least one of the displacement of the interface, the repetition rate, the shear application time, and the number of repetitions corresponding to the spacing between the interfaces of the fluid control region. Claim 4 A rheological pretreatment-based polymer drug delivery medical device according to claim 1, wherein the microneedles are provided in a plurality of numbers, and the flow path section includes a distribution section that distributes a drug solution supplied from the fluid control region into a plurality of branched flow paths each connected to the plurality of microneedles, and the plurality of branched flow paths are formed to have corresponding fluid resistances to reduce the flow rate variation of the drug solution supplied to the plurality of microneedles. Claim 5 A rheological pretreatment-based polymer drug delivery medical device according to claim 1, wherein the flow characteristic control unit reduces the viscosity of the drug solution by applying mechanical shear to the drug solution, and is configured to apply the mechanical shear within a range where the reduced viscosity is recoverable over time after the mechanical shear is terminated. Claim 6 A rheological pretreatment-based polymer drug delivery medical device according to claim 5, wherein the control unit controls the drug supply unit to supply the drug to the at least one microneedle by operating the drug supply unit within a time interval in which the reduced flow resistance is maintained at least partially after the flow resistance of the drug solution is reduced by the application of mechanical shear by the flow characteristic control unit. Claim 7 A rheological pretreatment-based polymer drug delivery medical device according to claim 6, wherein the control unit initiates the operation of the drug supply unit within 60 seconds after the termination of the mechanical shear, and controls the drug solution in a state where at least some of the reduced flow resistance is maintained to be supplied to the at least one microneedle. Claim 8 A rheological pretreatment-based polymer drug delivery medical device according to claim 1, wherein a deformable interface is provided along at least a portion of the fluid control region and the fluid channel, and the deformable interface is configured to sequentially deform from the fluid control region side toward the at least one microneedle side at the drug delivery termination stage to reduce the internal volume, thereby moving the drug remaining inside toward the at least one microneedle side. Claim 9 A rheological pretreatment-based polymer drug delivery medical device according to claim 1, further comprising a flow state detection unit for detecting state information indicating the supply of the drug solution or the operating state of the flow characteristic control unit, wherein the control unit is configured to control at least one of the operating condition of the flow characteristic control unit or the supply condition of the drug supply unit based on the state information detected by the flow state detection unit. Claim 10 A rheological pretreatment-based polymer drug delivery medical device according to claim 1, wherein the polymer comprises a polynucleotide (PN), a polydeoxyribonucleotide (PDRN), or a combination thereof. Claim 11 In claim 1, the flow characteristic controlling unit saturates the chemical solution for 500s -1 to 1500s -1 A rheological pretreatment-based polymer drug delivery medical device characterized by being configured to apply mechanical shear for 1 to 3 seconds at a shear rate. Claim 12 A rheological pretreatment-based polymer drug delivery medical device according to claim 1, wherein an outflow control unit is provided on the downstream side of the fluid control area to control the outflow of a drug moving from the fluid control area to the flow path side, and the control unit controls the outflow control unit to suppress the outflow of the drug from the fluid control area to the flow path side while mechanical shear is applied to the drug by the flow characteristic control unit, and controls the outflow control unit to supply the drug from the fluid control area to the flow path side after the mechanical shear is terminated. Claim 13 A rheological pretreatment-based polymer drug delivery medical device according to claim 12, wherein a backflow prevention member is provided on the upstream side of the fluid control region to suppress backflow of the drug from the fluid control region to the drug storage unit, and the backflow prevention member is configured to suppress upstream movement of the drug while mechanical shear is applied to the drug by the flow characteristic control member. Claim 14 A replaceable drug delivery cartridge detachably coupled to a drug delivery medical device for delivering a drug solution containing a polymer to skin tissue, comprising: an inlet into which the drug solution is introduced; a fluid control area through which the drug solution introduced through the inlet passes or is temporarily received; a shear generating structure that moves, vibrates, rotates, or deforms by a driving force transmitted from the outside to apply mechanical shear to the drug solution located in the fluid control area; a driving coupling part connected to the shear generating structure and detachably coupled to a driving source provided in the drug delivery medical device to transmit the driving force of the driving source to the shear generating structure; and at least one drug delivery path provided downstream of the fluid control area through which the drug solution to which the mechanical shear is applied moves. A replaceable drug delivery cartridge comprising: at least one microneedle that is provided to be insertable into skin tissue and delivers a drug solution supplied through at least one drug delivery route to the skin tissue; wherein the shear generating structure comprises at least one of a movable boundary forming the fluid control region, a shear member provided inside the fluid control region, or a structure forming the fluid control region. Claim 15 A replaceable liquid delivery cartridge according to claim 14, wherein the shear generating structure forms at least one boundary surface of the fluid control region and includes a shear membrane that moves or deforms by a driving force transmitted from the outside. Claim 16 A replaceable drug delivery cartridge according to claim 14, wherein the microneedles are provided in a plurality of numbers, and the replaceable drug delivery cartridge further comprises a distribution unit provided between the fluid control area and the plurality of microneedles to distribute the drug discharged from the fluid control area into a plurality of branching channels each connected to the plurality of microneedles. Claim 17 A replaceable drug delivery cartridge according to claim 14, wherein a discharge control unit is provided on the downstream side of the fluid control area to control the discharge of a drug liquid moving from the fluid control area to the at least one drug delivery path, and the discharge control unit is configured to suppress the discharge of the drug liquid from the fluid control area to the at least one drug delivery path while mechanical shear is applied to the drug liquid by the shear generation structure, and to discharge the drug liquid to the at least one drug delivery path after the mechanical shear is terminated. Claim 18 A replaceable liquid delivery cartridge according to claim 14, wherein the shear generating structure comprises at least a part or the whole of a structure forming the fluid control region, and the structure is driven by a driving force transmitted from the outside in a reciprocating motion, vibrating motion, rotational motion, eccentric rotational motion, oscillating motion, orbital motion, or a combination thereof, and a relative flow or velocity gradient is formed between the liquid and the interface of the structure or between different locations within the liquid by the driving of the structure. Claim 19 A replaceable liquid delivery cartridge according to claim 14, wherein the shear generating structure comprises a shear member provided inside the fluid control area, and the shear member is configured to move, reciprocate, vibrate, or rotate by a driving force transmitted from the outside to form a relative flow or velocity gradient between the liquid and the shear member or inside the liquid. Claim 20 A method for delivering a drug using a drug delivery medical device configured to supply a drug solution containing a polymer through at least one microneedle, comprising: a step of supplying a drug solution contained in a drug solution storage unit to a fluid control area provided downstream of the drug solution storage unit; a flow characteristic control step of applying mechanical shear to the drug solution located in the fluid control area before the drug solution is supplied to the at least one microneedle to temporarily reduce the flow resistance of the drug solution; a step of supplying the drug solution that has undergone the flow characteristic control step to at least one drug delivery path through a flow path provided downstream of the fluid control area; and a step of supplying the drug solution supplied to the at least one drug delivery path to the at least one microneedle side; characterized by comprising: a rheological pretreatment-based polymer drug delivery medical device. Claim 21 A method for delivering a drug using a rheological pretreatment-based polymer drug delivery medical device according to claim 20, wherein the flow characteristic control step is characterized by applying mechanical shear to a drug located in the fluid control region by displacing at least one interface forming the fluid control region relative to another interface while the at least one microneedle is supported independently of the relative displacement of the interface forming the fluid control region. Claim 22 A method for delivering a drug using a rheological pretreatment-based polymer drug delivery medical device according to claim 21, wherein the flow characteristic control step controls the mechanical shear applied to the drug by controlling at least one of the displacement of the interface, the repetition rate, the shear application time, and the number of repetitions corresponding to the spacing between the interfaces of the fluid control region. Claim 23 A method for delivering a drug using a rheological pretreatment-based polymer drug delivery medical device, wherein, in claim 20, the step of supplying the drug solution to the at least one microneedle is performed within a time interval in which the flow resistance of the drug solution, reduced by the flow characteristic control step, is maintained at least partially. Claim 24 A method for delivering a drug using a rheological pretreatment-based polymer drug delivery medical device, characterized in that, in the step of terminating the supply of the drug, a deformable interface forming at least a part of the fluid control region and the flow path is sequentially deformed from the side of the fluid control region toward the side of the at least one microneedle to reduce the internal volume, and the drug remaining in the fluid control region or the flow path is moved toward the side of the at least one microneedle. Claim 25 A method for delivering a drug using a rheological pretreatment-based polymer drug delivery medical device according to claim 20, wherein the flow characteristic control step and the step of supplying the drug solution to the at least one microneedle are performed in overlap for at least a portion of the time interval, and at least a portion of the drug solution is supplied to the at least one microneedle through the flow channel while mechanical shear is applied to the drug solution during the overlapped time interval. Claim 26 A method for delivering a drug using a rheological pretreatment-based polymer drug delivery medical device, wherein, in claim 20, the flow characteristic control step comprises: a step of suppressing the outflow of a drug from the fluid control region to the flow path side while mechanical shear is applied to the drug located in the fluid control region; and a step of supplying a drug from the fluid control region to the flow path side after the mechanical shear is terminated.

Citation Information

Patent Citations

  • Drug Delivery Devices

    JP2020504650A

  • Microneedle array assembly and fluid delivery apparatus having such an assembly

    KR1020180131630A

  • Microneedle applicator

    KR1020230017315A

  • Viscosity reduction

    US20110278153A1